T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$2.31B |
| 2 |
Apple
AAPL
|
+$1.58B |
| 3 |
Sherwin-Williams
SHW
|
+$1.37B |
| 4 |
HubSpot
HUBS
|
+$1.32B |
| 5 |
Kenvue
KVUE
|
+$1.25B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.37B |
| 2 |
Lam Research
LRCX
|
+$1.54B |
| 3 |
Applied Materials
AMAT
|
+$1.33B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.19B |
| 5 |
Halliburton
HAL
|
+$1.16B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.32% |
| 2 | Healthcare | 15.15% |
| 3 | Financials | 10.54% |
| 4 | Consumer Discretionary | 10.48% |
| 5 | Communication Services | 8.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLP
2751
DELISTED
Cantaloupe
CTLP
| $140K | ﹤0.01% |
18,821
+518
| +3% | +$3.56K |
|
2752
Omeros
OMER
$1.25B
| $140K | ﹤0.01% |
35,181
| – | – |
|
|
NXDR
2753
Nextdoor Holdings
NXDR
$986M
| $139K | ﹤0.01% |
55,650
-178,207
| -76% | -$458K |
|
2754
SkinHealth Systems
SKIN
$83.6M
| $138K | ﹤0.01% |
95,747
+19,300
| +25% | +$31.6K |
|
|
TSVT
2755
DELISTED
2seventy bio
TSVT
| $138K | ﹤0.01% |
29,212
+283
| +1% | +$1.28K |
|
|
URG
2756
Ur-Energy
URG
$533M
| $136K | ﹤0.01% |
113,738
+25,945
| +30% | +$31K |
|
2757
Cardiff Oncology
CRDF
$78.6M
| $132K | ﹤0.01% |
49,237
| – | – |
|
|
DFTX
2758
Definium Therapeutics
DFTX
$5.98B
| $131K | ﹤0.01% |
22,952
| – | – |
|
2759
MaxCyte
MXCT
$152M
| $130K | ﹤0.01% |
33,405
| – | – |
|
|
FFWM
2760
DELISTED
First Foundation Inc
FFWM
| $129K | ﹤0.01% |
20,574
+4,173
| +25% | +$26.7K |
|
2761
Groupon
GRPN
$872M
| $129K | ﹤0.01% |
13,100
| – | – |
|
2762
OmniAb
OABI
$500M
| $129K | ﹤0.01% |
30,267
+716
| +2% | +$3.1K |
|
2763
Rimini Street
RMNI
$448M
| $129K | ﹤0.01% |
69,429
| – | – |
|
2764
Fulcrum Therapeutics
FULC
$280M
| $128K | ﹤0.01% |
35,712
| – | – |
|
2765
Citizens
CIA
$202M
| $127K | ﹤0.01% |
34,900
| – | – |
|
|
BRY
2766
DELISTED
Berry Corp
BRY
| $126K | ﹤0.01% |
24,469
+292
| +1% | +$1.78K |
|
2767
Cardlytics
CDLX
$24.4M
| $126K | ﹤0.01% |
3,927
+770
| +24% | +$42.7K |
|
2768
Tango Therapeutics
TNGX
$4.31B
| $125K | ﹤0.01% |
16,185
+951
| +6% | +$9.07K |
|
2769
Getty Images
GETY
$133M
| $123K | ﹤0.01% |
32,071
| – | – |
|
2770
Mercer International
MERC
$32.9M
| $123K | ﹤0.01% |
18,123
| – | – |
|
|
TSE
2771
DELISTED
Trinseo
TSE
| $123K | ﹤0.01% |
23,900
| – | – |
|
2772
Atomera
ATOM
$224M
| $121K | ﹤0.01% |
45,700
+12,200
| +36% | +$38K |
|
|
IAUX
2773
i-80 Gold Corp
IAUX
$1.48B
| $121K | ﹤0.01% |
103,770
+20,706
| +25% | +$21.7K |
|
2774
Taysha Gene Therapies
TSHA
$2B
| $121K | ﹤0.01% |
59,719
-1,216,859
| -95% | -$2.67M |
|
2775
Inovio Pharmaceuticals
INO
$89.9M
| $120K | ﹤0.01% |
20,652
| – | – |
|
Similar funds
T. Rowe Price Associates's Q3 2024 Portfolio in Review
As of Q3 2024, T. Rowe Price Associates held 3,059 positions worth $869B, up 3.9% from $836B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Trading was light in Q3 2024: portfolio turnover was 4.3%. T. Rowe Price Associates opened 82 new positions and exited 51, leaving the 3,059-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2024 buy was Lineage Inc: 4,699,854 shares worth $368M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q3 2024, an estimated $2.31B increase.
- T. Rowe Price Associates's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $4.37B.
- T. Rowe Price Associates fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $75.2M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $869B portfolio in Q3 2024.
- T. Rowe Price Associates opened 82 new positions and closed 51 in Q3 2024.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $869B.
Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.